Novo Nordisk to slash prices of weightloss drugs in US

Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic. “This decision applies to all doses of these medicines and reflects Novo Nordisk’s commitment to […] The post Novo Nordisk to slash prices of weightloss drugs in US appeared first on Digital Journal.